title: Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives.
abstract: Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of antineoplastic agents. Several treatment regimens are used to address this problem. Fosaprepitant is a neurokinin-1 receptor blocker used in the prevention and treatment of CINV, especially for moderately and severely emetogenic chemotherapy. It is highly effective in the treatment of delayed CINV. Data from previous studies show that fosaprepitant is noninferior to aprepitant in the management of CINV. Fosaprepitant is given as a single-dose intravenous infusion, thus offering better patient compliance. The dose-limiting side effect of fosaprepitant is an infusion-related reaction, ranging from pain at the infusion site to thrombophlebitis. This side effect has been reported with coadministration of anthracycline agents.
authors.affiliation: Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA.
authors.forename: Nellowe
authors.initials: N
authors.lastname: Candelario
authors.affiliation: Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA.
authors.forename: Marvin Louis Roy
authors.initials: ML
authors.lastname: Lu
keywords: chemotherapy nausea and vomiting; fosaprepitant; neurokinin inhibitor